Advisory Committee on Immunization Practices, 31381 [2015-13312]
Download as PDF
<![CDATA[
31381
Federal Register / Vol. 80, No. 105 / Tuesday, June 2, 2015 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Activity
Mothers (interview) .........................................
Telephone consent and BD–STEPS questionnaire.
Written consent for bloodspot retrieval ..........
Online Occupational Questionnaire ...............
Written release for medical records review ...
Pulling and sending records ..........................
Mothers (consent for bloodspot retrieval) .......
Mothers (online occupational questionnaire) ..
Mothers (consent for medical records review)
Records reviewers (medical records review)
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–13385 Filed 6–1–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Advisory Committee on Immunization
Practices
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following federal advisory
committee meeting.
Times and dates:
8:00 a.m.–5:15 p.m., June 24, 2015
8:30 a.m.–3:30 p.m., June 25, 2015
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton
Road NE., Building 19, Kent ‘‘Oz’’
Nelson Auditorium, Atlanta, Georgia
30333
Status: Open to the public, limited
only by the space available. Time will
be available for public comment. The
public is welcome to submit written
comments in advance of the meeting.
Comments should be submitted in
writing by email to the contact person
listed below. The deadline for receipt is
June 22, 2015. All requests must contain
the name, address, and organizational
affiliation of the speaker, as well as the
topic being addressed. Written
comments should not exceed one singlespaced typed page in length and
delivered in three minutes or less.
Please note that the public comment
period may end before the time
indicated, following the last call for
comments. Members of the public who
wish to provide public comments
should plan to attend the public
comment session at the start time listed.
Written comments received in advance
VerDate Sep<11>2014
17:26 Jun 01, 2015
Jkt 235001
of the meeting will be included in the
official record of the meeting.
The meeting will be webcast live via
the World Wide Web; for instructions
and more information on ACIP please
visit the ACIP Web site: https://
www.cdc.gov/vaccines/acip/
Purpose: The committee is charged
with advising the Director, CDC, on the
appropriate use of immunizing agents.
In addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for
administration to vaccine-eligible
children through the Vaccines for
Children (VFC) program, along with
schedules regarding the appropriate
periodicity, dosage, and
contraindications applicable to the
vaccines. Further, under provisions of
the Affordable Care Act, at section 2713
of the Public Health Service Act,
immunization recommendations of the
ACIP that have been adopted by the
Director of the Centers for Disease
Control and Prevention must be covered
by applicable health plans.
Matters for discussion: The agenda
will include discussions on:
Meningococcal vaccines; general
recommendations; human
papillomavirus vaccines; influenza;
influenza A(H5N1) vaccine, tetanus,
diphtheria, and acellular pertussis
(Tdap) vaccine; combination vaccines;
smallpox vaccine in laboratory
personnel; pneumococcal vaccines;
child/adolescent immunization
schedule; herpes zoster vaccines;
Japanese encephalitis vaccine and
vaccine supply. Recommendation votes
are scheduled for meningococcal
vaccines, influenza, influenza A (H5N1),
smallpox vaccine in laboratory
personnel, general recommendations
and pneumococcal vaccines. A Vaccines
for Children (VCF) vote is scheduled for
meningococcal vaccines.
Agenda items are subject to change as
priorities dictate.
Contact person for more information:
Stephanie Thomas, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road NE., MS–A27,
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hours)
1,925
1
45/60
1,375
642
385
385
1
1
1
1
15/60
20/60
15/60
30/60
Atlanta, Georgia 30333, telephone 404/
639–8836; Email ACIP@CDC.GOV
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–13312 Filed 6–1–15; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to PA
07–318, NIOSH Member Conflict
Review.
Time and date: 1:00 p.m.–4:00 p.m.,
EST, June 25, 2015 (Closed)
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘NIOSH Member Conflict PA 07–318.’’
Contact person for more information:
Nina Turner, Ph.D., Scientific Review
E:\FR\FM\02JNN1.SGM
02JNN1
]]>Agencies
[Federal Register Volume 80, Number 105 (Tuesday, June 2, 2015)]
[Notices]
[Page 31381]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-13312]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announce the following federal advisory committee
meeting.
Times and dates:
8:00 a.m.-5:15 p.m., June 24, 2015
8:30 a.m.-3:30 p.m., June 25, 2015
Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia
30333
Status: Open to the public, limited only by the space available.
Time will be available for public comment. The public is welcome to
submit written comments in advance of the meeting. Comments should be
submitted in writing by email to the contact person listed below. The
deadline for receipt is June 22, 2015. All requests must contain the
name, address, and organizational affiliation of the speaker, as well
as the topic being addressed. Written comments should not exceed one
single-spaced typed page in length and delivered in three minutes or
less. Please note that the public comment period may end before the
time indicated, following the last call for comments. Members of the
public who wish to provide public comments should plan to attend the
public comment session at the start time listed. Written comments
received in advance of the meeting will be included in the official
record of the meeting.
The meeting will be webcast live via the World Wide Web; for
instructions and more information on ACIP please visit the ACIP Web
site: https://www.cdc.gov/vaccines/acip/
Purpose: The committee is charged with advising the Director, CDC,
on the appropriate use of immunizing agents. In addition, under 42
U.S.C. 1396s, the committee is mandated to establish and periodically
review and, as appropriate, revise the list of vaccines for
administration to vaccine-eligible children through the Vaccines for
Children (VFC) program, along with schedules regarding the appropriate
periodicity, dosage, and contraindications applicable to the vaccines.
Further, under provisions of the Affordable Care Act, at section 2713
of the Public Health Service Act, immunization recommendations of the
ACIP that have been adopted by the Director of the Centers for Disease
Control and Prevention must be covered by applicable health plans.
Matters for discussion: The agenda will include discussions on:
Meningococcal vaccines; general recommendations; human papillomavirus
vaccines; influenza; influenza A(H5N1) vaccine, tetanus, diphtheria,
and acellular pertussis (Tdap) vaccine; combination vaccines; smallpox
vaccine in laboratory personnel; pneumococcal vaccines; child/
adolescent immunization schedule; herpes zoster vaccines; Japanese
encephalitis vaccine and vaccine supply. Recommendation votes are
scheduled for meningococcal vaccines, influenza, influenza A (H5N1),
smallpox vaccine in laboratory personnel, general recommendations and
pneumococcal vaccines. A Vaccines for Children (VCF) vote is scheduled
for meningococcal vaccines.
Agenda items are subject to change as priorities dictate.
Contact person for more information: Stephanie Thomas, National
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton
Road NE., MS-A27, Atlanta, Georgia 30333, telephone 404/639-8836; Email
ACIP@CDC.GOV
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2015-13312 Filed 6-1-15; 8:45 am]
BILLING CODE 4160-18-P
